Supply of a common Adderall alternative is running low, further limiting options for US patients amid a national shortage of ADHD drugs that has lasted almost a year. Vyvanse, sold by Takeda Pharmaceutical Co., is in low inventory due to manufacturing issues, a company spokesperson told Bloomberg News.